ema semaglutide naion june 2025 The Effect of and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy 🟡 Semaglutide and NAION –

The agency's recommendation is conditional, meaning the benefits likely outweigh the downsides but more evidence is needed

Based on typical FDA New Drug Application timelines for novel incretin compounds and the Emirates Drug Establishment registration pathway that follows initial regulatory approval, UAE pharmacy availability is unlikely before 2029

Tirzepatide produces more weight loss than semaglutide, but individualized dosing with robust support can achieve similar outcomes using lower doses

Throughout the year, Trump has teased triple-digit tariffs unless pharma companies make significant investments in the U.S., and has also waged a war on high drug prices for Americans